DIFFUSE MACULAR OEDEMA
Intravitreal triamcinolone acetonide or bevacizumab produce better short-term results than grid laser in the treatment of diffuse macular oedema but all three treatments produce similar results at one year, a comparative study suggests. The study, which involved 126 eyes, showed that eyes receiving intravitreal bevacizumab or triamcinolone had higher rates of anatomical and functional success at six months than did eyes that underwent grid laser treatment (p < 0.05 for both). However, by one year there was no significant difference between the groups in terms of visual stabilisation
(Sobaci et al, Ophthalmologica 2012; 227: 95-99).Â
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.